Walldius G, Jungner I
King Gustaf V Research Institute and Karolinska Institute, Stockholm, Sweden.
J Intern Med. 2004 Feb;255(2):188-205. doi: 10.1046/j.1365-2796.2003.01276.x.
Although LDL cholesterol (LDL-C) is associated with an increased risk of coronary heart disease, other lipoproteins and their constituents, apolipoproteins, may play an important role in atherosclerosis. Elevated levels of apolipoprotein (apo) B, a constituent of atherogenic lipoproteins, and reduced levels of apo A-I, a component of anti-atherogenic HDL, are associated with increased cardiac events. Apo B, apo A-I and the apo B/apo A-I ratio have been reported as better predictors of cardiovascular events than LDL-C and they even retain their predictive power in patients receiving lipid-modifying therapy. Measurement of these apolipoproteins could improve cardiovascular risk prediction.
尽管低密度脂蛋白胆固醇（LDL-C）与冠心病风险增加相关，但其他脂蛋白及其成分载脂蛋白可能在动脉粥样硬化中起重要作用。致动脉粥样硬化脂蛋白的成分载脂蛋白B（apo）B水平升高，以及抗动脉粥样硬化高密度脂蛋白（HDL）的成分apo A-I水平降低，均与心脏事件增加有关。据报道，apo B、apo A-I和apo B/apo A-I比值比LDL-C能更好地预测心血管事件，甚至在接受调脂治疗的患者中仍保留其预测能力。检测这些载脂蛋白可改善心血管风险预测。
